PubMed Health⌕ Search

Biomedical subjects

Y Kunisawa

Publications and source records attributed to Y Kunisawa.

9 recordsLinked to original sources
PubMed1986

[Treatment of nongonococcal urethritis--studies on clinical effects of ofloxacin].

Clinical effects of ofloxacin (OFLX) in the treatment of chlamydial urethritis was compared with those in the treatment of non-chlamydial urethritis. Chlamydia trachomatis was isolated from 33 (39.3%) out of 84 patients with nongonococcal urethritis. OFLX was administered at a dose of 100 mg, three times daily (300 mg) for 14 days. In 31 (93.3%) of the 33 patients with chlamydial urethritis, C. trachomatis was eliminated within 7 to 14 days after the start of administration, and, in two patients, inclusion bodies decreased in number but persisted. The subjective and objective clinical symptoms, urethral discharge, polymorphonuclear leucocyte (PMNL) in smears, and pyuria in VB1 of the patients with chlamydial urethritis, disappeared in 56.0, 57.6, and 63.0% of the cases, and improved in 24.0, 30.0 and 29.6% respectively, whereas those of the patients with non-chlamydial urethritis, urethral discharge, PMNL, and pyuria in VB1 disappeared in 57.6, 56.9 and 32.9%, and improved in 26.9, 13.7 and 37.9%, respectively. There was no significant difference in the clinical effects of OFLX between cases of chlamydial urethritis and those of non-chlamydial urethritis. Marked improvement in clinical symptoms were observed between day 7 and day 14 of medication in cases of both chlamydial and non-chlamydial urethritis. In nine out of 11 cases of non-chlamydial urethritis where OFLX was ineffective, no Ureaplasma nor aerobes, nor C. trachomatis, were isolated. In the remaining two cases where Ureaplasma and S. epidermidis were isolated respectively, these two bacteria were eradicated after medication, but urethral discharge and PMNL remained unchanged.(ABSTRACT TRUNCATED AT 250 WORDS)

Adult↗
PubMed1986

[Multiple imaging procedures including MRI in bladder cancer].

Endoscopic photography, double contrast cystography, transurethral echography, X-ray CT scan, and MRI (magnetic resonance imaging) were utilized for the staging diagnosis of the four patients with carcinoma of the bladder. In the first case, a 70-year-old man, since all of the five imaging procedures suggested a superficial and pedunculated tumor, his bladder cancer was considered T1. The classification of stage T3 carcinoma was made for the second 86-year-old male. Because all of his imaging examinations showed a tumor infiltrating deep muscle and penetrating the bladder wall. The third case was a 36-year-old male. His clinical stage was diagnosed as T2 or T3a by cystophotography, double contrast cystogram, ultrasonography, and X-ray CT scan. However, MRI showed only thickened bladder wall and the infiltrating tumor could not be distinguished from the hypertrophic wall. The last patient, a 85-year-old female, had a smaller Ta cancer. Her double contrast cystography revealed the small tumor at the lateral bladder wall. But, the tumor could not be detected by transaxial, sagittal and coronal scans. Multiple imaging procedures combining MRI and staging diagnosis of the bladder carcinoma were discussed.

Adult↗
PubMed1986

[Synchronously diagnosed and treated triple cancer (rectum-ureter-prostate)].

A 63-year-old man was admitted for examination of a rectal tumor. A stony hard nodule was palpated in his swollen prostate by rectal examination. The biopsies proved rectal and prostate carcinoma. Transabdominal echogram and DIP showed left hydronephrosis. Left ureteral cancer was suggested by the typical "goblet sign" with retrograde ureterography. Rectal lower anterior resection, left total nephroureterectomy with partial cystectomy, castration and pelvic lymphadenectomy were undertaken synchronously. The pathohistological diagnosis was triple cancer consisting of rectal mucotubular adenocarcinoma, prostatic carcinoma and ureteral transitional cell carcinoma. The diagnosis and treatment of the triple cancer were discussed.

Adenocarcinoma↗
PubMed1986

[Changes in renal function on response to rapid administration of cisplatinum].

Seven patients with urologic carcinomas were examined for changes in renal function as a result of administration of Cisplatinum (CDDP) at a high rate of 50 or 100 mg/m2 within 5 hours, superimposing 2 liters of fluid before and after the CDDP dose, and the results were compared with the pretreatment values. Renal function tests revealed that BUN was elevated to 20 mg/dl or more in 5 but not beyond 30 mg/dl in any of the patients, that serum creatinine was elevated to 1.4 mg/dl or more in 3 cases with a maximum of 1.5 mg/dl, and that Ccr was decreased to less than 70% of the pretreatment value in 3 patients. These manifestations of imparied renal function were all transient and reversible, being mostly restored to the pretreatment values during or within 1 month after the end of CDDP treatment, and did not necessitate the discontinuation of the treatment in any patients. The above findings proved the rapid infusion of CDDP to be as safe in terms of renal function as prolonged, continued i.v. infusion of the drug, which would these fore make CDDP treatment of outpatients possible.

Aged↗
PubMed1985

A pharmacological study of alpha adrenergic receptor subtypes in smooth muscle of human urinary bladder base and prostatic urethra.

Postsynaptic alpha adrenergic receptor subtypes mediating contraction of human urinary bladder base and prostatic urethra were investigated in vitro. Alpha adrenergic receptor agonists, noradrenaline and phenylephrine, induced contraction dose-dependently in these tissues. Alpha adrenergic receptor antagonists, prazosin and yohimbine, competitively antagonized the contraction induced by these agonists in the bladder base as well as prostatic urethra. The mean pA2 values for the antagonists in the bladder base and prostatic urethra were as follows: 8.89 and 8.96 for prazosin and 6.30 and 6.45 for yohimbine, respectively. Comparison of pA2 values of prazosin and yohimbine in both the tissues with those values found in the literature for these compounds in a variety of tissues containing alpha-1 or alpha-2 adrenergic receptor indicates that the postsynaptic alpha adrenergic receptor subtype in the human urinary bladder base and prostatic urethra is the alpha-1 type, not the alpha-2 type.

Aged↗